The US launch of Amgen, Inc.’s Amjevita – the first biosimilar of AbbVie Inc.’s blockbuster Humira (adalimumab) – is off to a slow start. The company reported second quarter sales on 3 August, with US sales of Amjevita declining versus the first quarter, which the company attributed to inventory stocking associated with the launch in January.
Key Takeaways
- Amgen reported solid second quarter financial results, including 6% top-line growth.
Amgen had the US biosimilar market to itself initially following the product launch on 31 January, but other biosimilar versions...








